Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical
Progression‐free survival ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found